James Mc Keown

Mr. James Mc Keown


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2020 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ABAndrew J. Byrne
Andrew J. Byrne
SBSandra A. Bright
Sandra A. Bright
JKJames Mc Keown
James Mc Keown
JOJohn E. O’brien
John E. O’brien
BTBrendan Twamley
Brendan Twamley
Mary Jane MeeganMary Jane Meegan
Mary Jane Meegan
Lymphomas (cancers of the lymphatic system) account for 12% of malignant diseases worldwide. Burkitt’s lymphoma (BL) is a rare form of non-Hodgkin’s lymphoma in which the cancer starts in the immune B-cells. We report the synthesis and preliminary studies on the antiproliferative activity of a library of 9,10-dihydro-9,10-ethanoanthracene based compounds structurally related to the antidepressant drug maprotiline against BL cell lines MUTU-1 and DG-75. Structural modifications were achieved by Diels-Alder reaction of the core 9-(2-nitrovinyl)anthracene with number of dienophiles including maleic anhydride, maleimides, acrylonitrile and benzyne. The antiproliferative activity of these compounds was evaluated in BL cell lines EBV− MUTU-1 and EBV+ DG-75 (chemoresistant). The most potent compounds 13j, 15, 16a, 16b, 16c, 16d and 19a displayed IC50 values in the range 0.17–0.38 μM against the BL cell line EBV− MUTU-1 and IC50 values in the range 0.45–0.78 μM against the chemoresistant BL cell line EBV+ DG-75. Compounds 15, 16b and 16c demonstrated potent ROS dependent apoptotic effects on the BL cell lines which were superior to the control drug taxol and showed minimal cytotoxicity to peripheral blood mononuclear cells (PBMCs). The results suggest that this class of compounds merits further investigation as antiproliferative agents for BL.

14 December 2023 in Molecules
Verified
Journal Article
Open access
PDF file
ABAndrew Jam3s Byrne
Andrew Jam3s Byrne
SBSandra A. Bright
Sandra A. Bright
JKJames Mc Keown
James Mc Keown
ABAdam Bergin
Adam Bergin
BTBrendan Twamley
Brendan Twamley
Mary Jane MeeganMary Jane Meegan
Mary Jane Meegan
Chronic lymphocytic leukaemia (CLL) is a malignancy of the immune B lymphocyte cells and is the most common leukaemia diagnosed in developed countries. In this paper, we report the synthesis and antiproliferative effects of a series of (E)-9-(2-nitrovinyl)anthracenes and related nitrostyrene compounds in CLL cell lines and also in Burkitt’s lymphoma (BL) cell lines, a rare form of non-Hodgkin’s immune B-cell lymphoma. The nitrostyrene scaffold was identified as a lead structure for the development of effective compounds targeting BL and CLL. The series of structurally diverse nitrostyrenes was synthesised via Henry–Knoevenagel condensation reactions. Single-crystal X-ray analysis confirmed the structure of (E)-9-chloro-10-(2-nitrobut-1-en-1-yl)anthracene (19f) and the related 4-(anthracen-9-yl)-1H-1,2,3-triazole (30a). The (E)-9-(2-nitrovinyl)anthracenes 19a, 19g and 19i–19m were found to elicit potent antiproliferative effects in both BL cell lines EBV−MUTU-1 (chemosensitive) and EBV+ DG-75 (chemoresistant) with >90% inhibition at 10 μM. Selected (E)-9-(2-nitrovinyl)anthracenes demonstrated potent antiproliferative activity in CLL cell lines, with IC50 values of 0.17 μM (HG-3) and 1.3 μM (PGA-1) for compound 19g. The pro-apoptotic effects of the most potent compounds 19a, 19g, 19i, 19l and 19m were demonstrated in both CLL cell lines HG-3 and PGA-1. The (E)-nitrostyrene and (E)-9-(2-nitrovinyl)anthracene series of compounds offer potential for further development as novel chemotherapeutics for CLL.

5 August 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
JKJames Mc Keown
James Mc Keown
ABAndrew Jam3s Byrne
Andrew Jam3s Byrne
SBSandra A. Bright
Sandra A. Bright
CCClara Charleton
Clara Charleton
SKShubhangi Kandwal
Shubhangi Kandwal
Mary Jane MeeganMary Jane Meegan
Mary Jane Meegan
Chronic lymphocytic leukemia (CLL) is a malignancy of mature B cells, and it is the most frequent form of leukemia diagnosed in Western countries. It is characterized by the proliferation and accumulation of neoplastic B lymphocytes in the blood, lymph nodes, bone marrow and spleen. We report the synthesis and antiproliferative effects of a series of novel ethanoanthracene compounds in CLL cell lines. Structural modifications were achieved via the Diels–Alder reaction of 9-(2-nitrovinyl)anthracene and 3-(anthracen-9-yl)-1-arylprop-2-en-1-ones (anthracene chalcones) with dienophiles, including maleic anhydride and N-substituted maleimides, to afford a series of 9-(E)-(2-nitrovinyl)-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-12,14-diones, 9-(E)-3-oxo-3-phenylprop-1-en-1-yl)-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-12,14-diones and related compounds. Single-crystal X-ray analysis confirmed the structures of the novel ethanoanthracenes 23f, 23h, 24a, 24g, 25f and 27. The products were evaluated in HG-3 and PGA-1 CLL cell lines (representative of poor and good patient prognosis, respectively). The most potent compounds were identified as 20a, 20f, 23a and 25n with IC50 values in the ranges of 0.17–2.69 µM (HG-3) and 0.35–1.97 µM (PGA-1). The pro-apoptotic effects of the potent compounds 20a, 20f, 23a and 25n were demonstrated in CLL cell lines HG-3 (82–95%) and PGA-1 (87–97%) at 10 µM, with low toxicity (12–16%) observed in healthy-donor peripheral blood mononuclear cells (PBMCs) at concentrations representative of the compounds IC50 values for both the HG-3 and PGA-1 CLL cell lines. The antiproliferative effect of the selected compounds, 20a, 20f, 23a and 25n, was mediated through ROS flux with a marked increase in cell viability upon pretreatment with the antioxidant NAC. 25n also demonstrated sub-micromolar activity in the NCI 60 cancer cell line panel, with a mean GI50 value of 0.245 µM. This ethanoanthracene series of compounds offers potential for the further development of lead structures as novel chemotherapeutics to target CLL.

3 November 2018
Verified
Conference Paper
Open access
Mary Jane MeeganMary Jane Meegan
Mary Jane Meegan
JKJames Mc Keown
James Mc Keown
CCClara Charleton
Clara Charleton
KFKeith Ferris
Keith Ferris
SNSara Noorani
Sara Noorani
NONiamh O'Boyle
Niamh O'Boyle
CLL (Chronic Lymphocytic Leukaemia) is the most common leukaemia in the Western world. Classed as a clonal disorder of mature B-lymphocytes, CLL patient prognoses are broadly subdivided by the mutational status of the Immunoglobulin G Heavy Chain Variable region (IGHV) (with unmutated IGHV holding a better patient prognosis than the wild type variant)1. Structures related to tricyclic and tetracyclic anti-depressants (fluoxetine,maprotiline respectively) have previously been shown to exert potent, selective antiproliferative and pro-apoptotic effects in vitro and were met with marked success in related B cell malignancy cell lines, namely Burkitt’s Lymphoma (BL) cell lines DG-75 and MUTU-12. Based on these preliminary studies, libraries of structurally related novel ethanoanthracene compounds were designed, based on the proven effectiveness of nitrostyrene core moiety derivatives and literature evidence of selective toxicity of chalcone moieties in leukaemic cell lines3. The antiproliferative activity of each compound was determined using Alamar Blue assays on the two types of CLL cell lines: HG-3 and PGA-1, representative of bad and good prognosis respectively. The most promising activity was observed with maleimide dienophile based ethanoanthracene chalcones, particularly at a 10 µM across both cell lines. A ROS (reactive oxygen species) dependant activity was noted as both nitrostyrene and chalcone based analog biological activity markedly decreased on addition of NAC (N- acetyl cysteine) or Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid). References Scarfò, L.; Ferreri, A. J. M.; Ghia, P., Critical Reviews in Oncology/Hematology, 2016, 104, 169-182. Mc Namara, Y. M., Bright, S.A., Byrne, A.J., Williams, D.C., Meegan, M.J., European Journal of Medicinal Chemistry 2014, 71, 333. Zhuang, C.; Zhang, W.; Sheng, C.; Zhang, W.; Xing, C.; Miao, Z., Chemical Reviews, 2017, 117(12):7762-7810.